首页> 外文期刊>Thyroid: official journal of the American Thyroid Association >Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management
【24h】

Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management

机译:甲状腺癌患者的放射性碘治疗:外部剂量率衰减法和个性化患者管理的研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Therapy with radioactive iodine (~(131)I) is a well established treatment method for postsurgical differentiated thyroid carcinoma (DTC). A fixed discharge time is generally set, regardless of individual differences in residual body radioactivity (RBA). This study aimed to investigate the RBA of each patient to find the attenuation law and to identify underlying factors in order to predict the time point for a safe, scientifically sound discharge plan. Methods: A total of 231 DTC patients undergoing ~(131)I treatment were all treated with 3.7 GBq (100 mCi) of ~(131)I. RBA was estimated by measuring the external body dose rate (EDR) at a distance of 1 m from the body surface between 0 and 72 hours after oral administration of ~(131)I. Data from each patient were used to establish a time–EDR value (h–μSv/h) curve. Software was developed to predict the time when a patient's dose equivalent meets the national safety standard by including six time points between 40 and 60 hours. Several factors that might affect that time were analyzed. Results: The EDR attenuation law in patients could be described with a double exponential decay model, and the cutoff value was set as 23.3 μSv/h, upon which the predictive software was developed. Student's t -test showed there was no statistical difference between predicted values and the actual measured values ( p > 0.05). Correlation analysis found that serum thyroglobulin, total triiodothyronine, total thyroxine, free triiodothyronine, free thyroxine, thyrotropin, 2- and 24-hour iodine uptake rate of the thyroid, scores of ~(99m)Tc-pertechnetate thyroid scan, scores of ~(131)I whole-body scan, scores of ultrasound scan, and gastrointestinal residues were associated with attenuation speed. A further multiple linear regression analysis found that 24-hour iodine uptake ( X _(1)), residual thyroid grading by ~(131)I whole-body scan ( X _(2)), blood free triiodothyronine ( X _(3)) and free thyroxine ( X _(4)) predominantly influenced the decline of the EDR. The regression equation was ? = 2.091 X _(1) + 6.370 X _(2) + 4.529 X _(3) + 2.466 X _(4) – 8.614 ( F = 44.03, p Conclusions: An effective and convenient method was created to measure and predict the individual safety time for discharge. This could play a significant role not only for scientific hospital discharge planning, rational use of medical resources, and better individualized management, but also in public radiation protection.
机译:背景:放射性碘的治疗(〜(131)i)是后勤分化甲状腺癌(DTC)的良好的处理方法。无论残差体放射性(RBA)中的个体差异如何,通常都设定固定放电时间。本研究旨在调查每位患者的RBA寻找衰减法并确定潜在因素,以预测安全,科学声音排放计划的时间点。方法:进行231名正在进行的231例DTC患者〜(131)治疗均用3.7GBQ(100mci)的〜(131)i。通过在口服施用〜(131)I的口服〜72小时之间从体表距离体表的距离为1μm的距离,估计RBA。来自每个患者的数据用于建立时间EDR值(H-μSV/ h)曲线。制定了软件以预测患者剂量等同物符合国家安全标准的时间,包括六个时间点在40至60小时之间。分析了可能影响该时间的几个因素。结果:可以用双指数衰减模型描述患者EDR衰减法,截止值设定为23.3μSV/ h,开发了预测软件。学生的T -Test显示预测值与实际测量值之间没有统计差异(p> 0.05)。相关性分析发现,血清甲状腺球蛋白,总三碘甲醇,总甲状腺素,游离三碘甲肾上腺素,游离甲状腺素,甲状腺素,2-〜24小时碘摄取率的甲状腺,得分〜(99m)TC-Perthnetate甲状腺扫描,得分〜( 131)我全身扫描,超声扫描的分数,胃肠残留物与衰减速度相关。进一步的多元线性回归分析发现,24小时碘摄取(x _(1)),残留的甲状腺分级〜(131)I全身扫描(x _(2)),无流动三碘罗酮(x _(3 ))和游离甲状腺素(X _(4))主要影响EDR的衰落。回归方程是? = 2.091 x _(1)+ 6.370 x _(2)+ 4.529 x _(3)+ 2.466 x _(4) - 8.614(f = 44.03,P结论:创建了有效和方便的方法来衡量和预测单独的出院安全时间。这可能不仅可以为科学院出院规划,合理使用医疗资源以及更好的个性化管理,而且还在公共辐射防护方面发挥重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号